Pharmacology of Acetazolamide

Introduction/Overview

Acetazolamide represents a cornerstone therapeutic agent within the class of carbonic anhydrase inhibitors, distinguished by its unique mechanism of action and diverse clinical applications. First introduced in the 1950s, it remains a critical drug in the management of several conditions, ranging from ophthalmic disorders to neurological and respiratory ailments. Its primary action, the inhibition of the enzyme carbonic anhydrase, precipitates a cascade of physiological effects that are harnessed for therapeutic benefit. The clinical relevance of acetazolamide is underscored by its utility in treating pathologies where the modulation of fluid secretion, ion transport, or acid-base balance is required. Its importance extends beyond first-line therapy, often serving as an adjunctive agent or a treatment for specific, refractory conditions.

Learning Objectives

Upon completion of this chapter, the reader should be able to:

• Describe the molecular mechanism of action of acetazolamide as a carbonic anhydrase inhibitor and explain the subsequent physiological consequences.
• Outline the fundamental pharmacokinetic properties of acetazolamide, including its absorption, distribution, metabolism, and excretion.
• List the primary approved therapeutic indications for acetazolamide and rationalize its use based on its pharmacodynamic effects.
• Identify the common and serious adverse effects associated with acetazolamide therapy and discuss strategies for their management.
• Analyze significant drug-drug interactions and special population considerations relevant to the safe prescribing of acetazolamide.

Classification

Acetazolamide is systematically classified within specific therapeutic and chemical categories that define its clinical use and properties.

Therapeutic and Pharmacological Classification

The primary classification of acetazolamide is as a carbonic anhydrase inhibitor. Within this broader class, it serves multiple therapeutic roles:

• Diuretic: Specifically, it is categorized as a non-thiazide or non-loop diuretic, often termed an “inhibitory diuretic” due to its distinct mechanism. Its diuretic effect is mild and self-limiting, differentiating it from more potent agents like furosemide.
• Antiglaucoma Agent: It is a systemic agent used to lower intraocular pressure in various forms of glaucoma.
• Antiepileptic: It is considered an adjunctive agent for certain seizure types, particularly absence seizures.
• Prophylactic Agent for Altitude Sickness: It is used for the prevention and treatment of acute mountain sickness and related conditions.

Chemical Classification

Chemically, acetazolamide is a sulfonamide derivative. Its systematic name is N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide. The presence of the unsubstituted sulfonamide group (-SO₂NH₂) is critical for its activity, as it binds to the zinc ion within the active site of carbonic anhydrase. This structure distinguishes it from antibacterial sulfonamides, though it shares the potential for cross-reactivity in individuals with sulfa allergies. Acetazolamide is a white to yellowish-white crystalline powder that is slightly soluble in water.

Mechanism of Action

The therapeutic and adverse effects of acetazolamide are entirely attributable to its potent and reversible inhibition of the enzyme carbonic anhydrase. This inhibition occurs at the molecular level and manifests in significant cellular and systemic physiological changes.

Molecular and Enzymatic Mechanism

Carbonic anhydrase (CA) is a zinc-containing metalloenzyme that catalyzes the reversible hydration of carbon dioxide to carbonic acid, which subsequently dissociates into bicarbonate and a proton: CO₂ + H₂O ⇌ H₂CO₃ ⇌ HCO₃^– + H⁺. This reaction is fundamental to numerous physiological processes involving ion transport, fluid secretion, and acid-base homeostasis.

Acetazolamide acts as a non-competitive inhibitor by directly binding to the zinc ion (Zn²⁺) cofactor within the enzyme’s active site. The sulfonamide group (-SO₂NH^–) deprotonates at physiological pH, and the negatively charged nitrogen atom coordinates with the positively charged zinc ion, displacing the hydroxide ion (OH^–) that is normally essential for the catalytic cycle. This binding is tight and reversible, with a very high affinity, effectively blocking the enzyme’s catalytic activity.

Multiple isozymes of carbonic anhydrase exist (CA-I, CA-II, CA-IV, etc.), with varying tissue distributions. Acetazolamide is a non-selective inhibitor but has particularly high affinity for CA-II, the predominant cytosolic isozyme found in red blood cells, renal tubules, and the ciliary body of the eye. Inhibition of CA-II is primarily responsible for its systemic therapeutic effects.

Cellular and Systemic Pharmacodynamics

The inhibition of carbonic anhydrase leads to a cascade of effects across different organ systems.

Renal Effects (Diuretic Action)

In the kidney, carbonic anhydrase is abundant in the proximal convoluted tubule (PCT), where it plays a critical role in sodium bicarbonate (NaHCO₃) reabsorption. The enzyme facilitates the generation of H⁺ ions within the tubular cell, which are then secreted into the lumen via a Na⁺/H⁺ exchanger (NHE3). In the lumen, H⁺ combines with filtered HCO₃^– to form H₂CO₃, which is dehydrated to CO₂ and H₂O. CO₂ diffuses back into the cell, where it is rehydrated, completing the cycle and effectively reabsorbing HCO₃^–.

Acetazolamide inhibits luminal and cytosolic CA in the PCT. This blockade results in:

• Reduced secretion of H⁺ ions into the tubular lumen.
• Impaired reabsorption of filtered bicarbonate (HCO₃^–).
• Increased excretion of bicarbonate, sodium, potassium, and water, producing a mild diuresis.
• The urine becomes alkaline due to the bicarbonaturia.
• Systemically, a hyperchloremic metabolic acidosis develops due to the loss of bicarbonate. This acidosis is self-limiting; as plasma bicarbonate levels fall, the filtered load decreases, and the diuretic effect diminishes within 2-3 days (tolerance develops).

Ocular Effects (Lowering of Intraocular Pressure)

In the eye, carbonic anhydrase isoenzymes (primarily CA-II and CA-IV) are present in the ciliary epithelium, which is responsible for the secretion of aqueous humor. Aqueous humor formation involves the active transport of sodium and bicarbonate ions into the posterior chamber, followed by osmotic water movement.

Inhibition of carbonic anhydrase in the ciliary processes reduces bicarbonate ion production, which subsequently decreases sodium transport. This reduces the osmotic gradient, leading to a 30-40% decrease in the rate of aqueous humor production. The reduced inflow lowers intraocular pressure (IOP), which is beneficial in glaucoma.

Central Nervous System Effects

The mechanism for its antiepileptic effect, particularly in absence seizures, is not fully elucidated but is believed to involve the induction of a mild metabolic acidosis. This systemic acidosis may alter the pH of the central nervous system, which can stabilize neuronal membranes and raise the seizure threshold. An alternative hypothesis suggests that inhibition of brain carbonic anhydrase may directly affect ion gradients and GABAergic neurotransmission.

For altitude sickness prophylaxis, the drug-induced metabolic acidosis causes hyperventilation by lowering the set point for alveolar ventilation via the central chemoreceptors. This compensatory respiratory alkalosis (in response to the metabolic acidosis) enhances acclimatization by increasing alveolar oxygen and carbon dioxide exchange at high altitudes, thereby mitigating hypoxemia.

Other Systemic Effects

Inhibition of carbonic anhydrase in other tissues can explain additional effects. For instance, in the choroid plexus, reduced enzyme activity decreases cerebrospinal fluid (CSF) production, which may be useful in conditions like idiopathic intracranial hypertension (pseudotumor cerebri).

Pharmacokinetics

The pharmacokinetic profile of acetazolamide influences its dosing regimens, onset and duration of action, and potential for accumulation in special populations.

Absorption

Acetazolamide is generally well absorbed from the gastrointestinal tract following oral administration. Bioavailability is estimated to be high, though precise figures may vary. Peak plasma concentrations (C_max) are typically achieved within 1 to 3 hours (t_max) after an oral dose. The absorption process is not significantly affected by food, although taking it with meals may be recommended to minimize gastrointestinal upset. An intravenous formulation is available for use when oral administration is not feasible, providing a more rapid onset of action.

Distribution

Acetazolamide exhibits widespread distribution throughout body tissues and fluids. It readily crosses the blood-brain barrier and the placenta, and it is distributed into aqueous humor, red blood cells, and cerebrospinal fluid. The volume of distribution (V_d) is approximately 0.2 L/kg, suggesting distribution primarily within the extracellular fluid compartment. Plasma protein binding is moderate, ranging from 70% to 90%, primarily to albumin. This binding is saturable at higher therapeutic doses.

Metabolism

Acetazolamide undergoes minimal hepatic metabolism. The majority of the drug is excreted unchanged. It is not a substrate for, nor does it significantly induce or inhibit, major cytochrome P450 enzyme systems. This characteristic minimizes its potential for pharmacokinetic drug interactions mediated by metabolic pathways.

Excretion

The primary route of elimination is renal excretion via glomerular filtration and active tubular secretion. Within 24 hours, approximately 70% to 100% of an administered dose is recovered unchanged in the urine. The renal clearance of acetazolamide exceeds the glomerular filtration rate, confirming the role of active tubular secretion. The elimination half-life (t_1/2) is approximately 6 to 9 hours in subjects with normal renal function. Consequently, multiple daily dosing is often required to maintain therapeutic effects.

Pharmacokinetic Parameters and Dosing Considerations

The relationship between dose, plasma concentration, and effect is relatively linear within the therapeutic range. However, due to the development of tolerance to its diuretic effect, dosing for conditions like glaucoma or epilepsy is typically continuous, while for altitude sickness, it is short-term and prophylactic. In renal impairment, excretion is delayed, leading to drug accumulation, prolonged half-life, and an increased risk of toxicity. Dosing must be adjusted or the drug avoided in patients with significant renal dysfunction. Hepatic impairment does not significantly alter its pharmacokinetics, as metabolism is negligible.

Therapeutic Uses/Clinical Applications

The clinical applications of acetazolamide are directly linked to the physiological consequences of carbonic anhydrase inhibition in specific organ systems.

Approved Indications

Glaucoma

Acetazolamide is used as an adjunctive therapy for lowering intraocular pressure (IOP) in various forms of glaucoma, including open-angle glaucoma and angle-closure glaucoma. It is particularly useful in acute angle-closure glaucoma as a temporizing measure prior to definitive laser or surgical intervention. It is also employed in secondary glaucomas and pre- or post-operatively in other ophthalmic surgeries to control IOP. Due to its systemic side effects, it is generally not a first-line long-term therapy but is reserved for cases where topical agents are insufficient.

Epilepsy

It is indicated as an adjunctive treatment for generalized absence (petit mal) seizures, as well as for partial and generalized tonic-clonic seizures. Its use in epilepsy has declined with the advent of newer antiepileptic drugs with more favorable side effect profiles, but it remains an option for refractory cases.

Altitude Sickness

Acetazolamide is approved for the prevention and treatment of symptoms of acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE). Prophylactic administration, typically starting 24-48 hours before ascent and continuing for 48 hours after reaching the target altitude, can significantly reduce the incidence and severity of AMS. The mechanism involves the induction of a metabolic acidosis that stimulates ventilation and improves oxygenation.

Diuresis

As a diuretic, it is indicated in the management of edema due to congestive heart failure or drug-induced edema. However, its use for this purpose is limited due to the development of tolerance and the availability of more potent and reliable diuretics like loop diuretics.

Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)

While not always a formally labeled indication in all regions, acetazolamide is a well-established first-line pharmacological therapy for IIH. By inhibiting carbonic anhydrase in the choroid plexus, it reduces cerebrospinal fluid production, thereby lowering intracranial pressure and alleviating symptoms such as headache and papilledema.

Off-Label and Less Common Uses

• Metabolic Alkalosis: May be used to correct metabolic alkalosis, particularly when chloride-resistant (e.g., due to excessive diuretic use), by promoting bicarbonate excretion.
• Periodic Paralysis: Used in the prophylactic management of hypokalemic and hyperkalemic periodic paralysis, potentially by stabilizing muscle membrane potential through effects on pH and potassium shifts.
• Cystinuria: Can alkalinize urine, increasing the solubility of cystine and helping to prevent stone formation.
• Central Sleep Apnea: Sometimes used to reduce the frequency of central apneas, likely by stabilizing respiratory control through its acid-base effects.

Adverse Effects

The adverse effect profile of acetazolamide is extensive and is a direct extension of its pharmacological action, often limiting its long-term use.

Common Side Effects

These effects are frequently observed and are often dose-related and manageable.

• Paresthesias: A tingling or “pins and needles” sensation, especially in the fingers, toes, and perioral region, is very common. It results from the drug-induced metabolic acidosis affecting peripheral nerve function.
• Gastrointestinal Disturbances: Anorexia, nausea, vomiting, diarrhea, and altered taste (particularly a metallic taste for carbonated beverages) are frequently reported.
• Polyuria: Increased urine output is expected due to its diuretic action, especially during initial therapy.
• Fatigue, Drowsiness, and Confusion: Central nervous system effects can occur, particularly at higher doses.
• Metabolic Effects: Hyperchloremic metabolic acidosis and hypokalemia are predictable biochemical consequences. Hypokalemia results from increased distal tubular delivery of sodium and subsequent potassium secretion.

Serious and Rare Adverse Reactions

While less common, these reactions require immediate attention and often necessitate drug discontinuation.

• Sulfonamide Hypersensitivity Reactions: As a sulfonamide derivative, acetazolamide can cause severe allergic reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. These are idiosyncratic and not dose-related.
• Nephrolithiasis (Kidney Stones):strong> The drug can promote calcium phosphate stone formation due to the alkaline urine and increased urinary excretion of calcium and phosphate. It also reduces urinary citrate, a stone inhibitor.
• Severe Metabolic Acidosis: In patients with pre-existing acidosis, renal impairment, or severe respiratory disorders, the drug-induced acidosis can become severe and dangerous.
• Fulminant Hepatic Failure: Although rare, severe hepatotoxicity has been reported and can be fatal.
• Teratogenicity: Use during pregnancy, particularly in the first trimester, has been associated with congenital malformations in animal studies and some human case reports.

Black Box Warnings and Contraindications

Acetazolamide does not carry a formal FDA black box warning. However, its contraindications are stringent and include:

• Known hypersensitivity to acetazolamide, other sulfonamides, or any component of the formulation.
• Adrenal gland failure (Addison’s disease) or hyperchloremic acidosis.
• Severe renal disease (anuria, significant renal dysfunction) or hyperchloremic acidosis.
• Severe hepatic disease or cirrhosis, due to the risk of precipitating hepatic encephalopathy from decreased ammonia excretion.
• Conditions associated with severe electrolyte depletion (e.g., hypokalemia, hyponatremia).

Drug Interactions

Acetazolamide participates in several clinically significant pharmacokinetic and pharmacodynamic drug interactions.

Major Pharmacodynamic Interactions

• Other Diuretics: Concurrent use with thiazide or loop diuretics can lead to additive effects on potassium excretion, resulting in profound hypokalemia. This combination also increases the risk of metabolic acidosis.
• Drugs Causing Hypokalemia: Amphotericin B, corticosteroids, and stimulant laxatives can exacerbate acetazolamide-induced hypokalemia.
• Salicylates (e.g., Aspirin, High-Dose): A complex interaction exists. High-dose salicylates can cause metabolic acidosis and also displace acetazolamide from plasma proteins. Acetazolamide, by alkalinizing the urine, increases the renal excretion of salicylate in its ionized form. This can lead to either salicylate toxicity (if acetazolamide is stopped) or reduced salicylate efficacy. Concurrent use requires careful monitoring.
• Antiepileptic Drugs (e.g., Phenytoin, Carbamazepine): Acetazolamide may alter the pH of urine and blood, potentially affecting the ionization, protein binding, and distribution of other antiepileptics, though the clinical significance is variable.
• Cyclosporine: Acetazolamide-induced metabolic acidosis may increase the risk of cyclosporine nephrotoxicity.
• Methenamine: Acetazolamide alkalinizes the urine, which renders methenamine ineffective, as methenamine requires an acidic urine to convert to formaldehyde.

Pharmacokinetic Interactions

As acetazolamide is not metabolized by CYP450 enzymes and is primarily renally excreted, it has few pharmacokinetic interactions. However, drugs that compete for renal tubular secretion (e.g., probenecid) may theoretically increase acetazolamide plasma levels by reducing its excretion.

Contraindications Based on Interactions

Concomitant use with high-dose aspirin or other salicylates in chronic settings is generally contraindicated due to the risk of severe metabolic disturbances and salicylate toxicity. Use with other carbonic anhydrase inhibitors (e.g., topical dorzolamide) is also not recommended due to additive systemic effects.

Special Considerations

The use of acetazolamide requires careful evaluation and monitoring in specific patient populations due to altered pharmacokinetics, increased susceptibility to adverse effects, or teratogenic risk.

Pregnancy and Lactation

Pregnancy Category C (under the former FDA classification system). Animal studies have demonstrated teratogenicity, including limb and vertebral malformations. Human data are limited but suggest a potential risk. Acetazolamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It crosses the placenta and may cause neonatal metabolic acidosis, diuresis, and electrolyte disturbances.

Acetazolamide is excreted in human breast milk in low concentrations. Due to the potential for serious adverse reactions in nursing infants, such as metabolic acidosis and diuresis, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Considerations

Acetazolamide is used in children for indications such as epilepsy, glaucoma, and idiopathic intracranial hypertension. Dosing is typically based on body weight or surface area. Children may be more susceptible to metabolic acidosis and electrolyte imbalances. Close monitoring of growth, acid-base status, and electrolytes is essential. The risk of kernicterus in neonates, due to displacement of bilirubin from albumin, is a theoretical concern.

Geriatric Considerations

Elderly patients often have age-related declines in renal function, which can lead to reduced clearance and accumulation of acetazolamide. This population is also more susceptible to electrolyte disturbances (hypokalemia), dehydration, and confusion. Lower initial doses and careful monitoring of renal function and electrolytes are recommended. The increased prevalence of glaucoma in this population must be balanced against these risks.

Renal Impairment

Renal impairment is a major consideration. As the drug is primarily eliminated by the kidneys, any reduction in glomerular filtration rate (GFR) or tubular secretion will prolong its half-life and increase the risk of toxicity, particularly severe metabolic acidosis. Acetazolamide is contraindicated in patients with significant renal dysfunction (e.g., creatinine clearance below 10-30 mL/min, depending on sources) and in those with hyperchloremic acidosis or renal failure. In mild to moderate impairment, dose reduction and frequent monitoring of serum electrolytes and pH are mandatory.

Hepatic Impairment

Acetazolamide is contraindicated in severe hepatic impairment or cirrhosis. The drug-induced metabolic acidosis can impair the renal excretion of ammonium ions, potentially precipitating or exacerbating hepatic encephalopathy. In patients with mild to moderate liver disease, use with extreme caution and close monitoring.

Summary/Key Points

Acetazolamide is a prototypical sulfonamide-derived carbonic anhydrase inhibitor with a multifaceted pharmacological profile.

Bullet Point Summary

• The primary mechanism of action is the potent, reversible inhibition of carbonic anhydrase isoenzymes, particularly CA-II, by binding to the zinc ion in the active site.
• Systemic effects include reduced bicarbonate reabsorption in the kidney (causing diuresis and metabolic acidosis), decreased aqueous humor production in the eye (lowering IOP), reduced CSF production, and stimulation of ventilation via acid-base changes.
• Pharmacokinetically, it is well absorbed orally, widely distributed (including to CNS and eye), minimally metabolized, and predominantly renally excreted unchanged with a half-life of 6-9 hours.
• Major clinical indications are glaucoma (adjunctive), altitude sickness prophylaxis/treatment, adjunctive epilepsy therapy, and idiopathic intracranial hypertension.
• Common adverse effects are paresthesias, GI disturbances, fatigue, metabolic acidosis, and hypokalemia. Serious risks include sulfonamide hypersensitivity reactions, nephrolithiasis, and severe hepatotoxicity.
• Significant drug interactions exist with salicylates (contraindicated in chronic high-dose use), other diuretics (additive hypokalemia), and drugs that alkalinize or acidify urine.
• It is contraindicated in sulfa allergy, severe renal/hepatic impairment, adrenal insufficiency, and pre-existing metabolic acidosis. Extreme caution is required in pregnancy, lactation, and the elderly.

Clinical Pearls

• The development of tolerance to the diuretic effect within days limits its utility for chronic edema but does not affect its efficacy in glaucoma or altitude sickness when used appropriately.
• Paresthesias and altered taste are often the most bothersome side effects for patients but are generally not dangerous. Patient education can improve adherence.
• Monitoring should include baseline and periodic serum electrolytes (especially potassium and chloride), bicarbonate levels, and complete blood counts, particularly early in therapy.
• For altitude sickness, dosing should begin 24-48 hours before ascent; it is a prophylactic agent and less effective for treating established severe AMS once symptoms have progressed.
• Given its sulfonamide structure, a detailed allergy history must be obtained prior to prescription. Cross-reactivity with antibacterial sulfonamides, sulfonylureas, and thiazide diuretics is possible but not absolute.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.